Propanc Biopharma advances PRP toward first-in-human Phase 1b solid tumor trial in Australia
PPCB•Study design and manufacturing plans
The study design calls for open-label dose escalation and expansion to assess safety, PK/PD, and early antitumor activity, with weekly IV dosing.
Part A uses a BOIN dose-escalation approach to set up to two recommended doses; Part B adds tumor-specific expansion cohorts.
Management expects GMP manufacturing to start this year, positioning PRP for initial clinical readouts once enrollment begins.
Trial protocol being finalized for up to 40 patients
Propanc Biopharma began finalizing a first-in-human Phase 1b trial protocol for PRP in up to 40 advanced solid-tumor patients. Avance Clinical will lead feasibility work across Australian sites ahead of a planned Q4 clinical trial application submission.
